Arkolith/Insider Trading/XERS/Form 4

Sherman Jeffrey W

DirectorXeris Biopharma Holdings, Inc. (XERS) · full profile →Form 4 · filed Aug 29, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$334K
Net Open-Market Flow
-$334K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 28, 2025Option exercise(M)47K$6.66$313K261K
Aug 28, 2025Sell(S)42K$7.92$334K219K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 28, 2025Option exercise(M)47K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001867096-25-000145) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML